Product Description
FTL1 Antibody [FTL/1386] | 33-711 | ProSci
Host: Mouse
Reactivity: Human
Homology: N/A
Immunogen: Amino acids 38-165 of human FTL were used as the immunogen for this Ferritin Light Chain antibody.
Research Area: Obesity, Neuroscience, Signal Transduction
Tested Application: WB, Flow, IHC, IF
Application: Western blot: 0.1-0.2 ug/ml
Flow Cytometry: 0.1-0.2ug/10^6 cells
IF: 0.1-0.2 ug/ml
IHC (FFPE) : 0.1-0.2 ug/ml for 30 min at RT
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the Ferritin Light Chain antibody to be titered up or down for optimal performance.
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: N/A
Validation: N/A
Isoform: N/A
Purification: Protein G affinity chromatography
Clonality: Monoclonal
Clone: FTL/1386
Isotype: IgG2b
Conjugate: Unconjugated
Physical State: Liquid
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.
Alternate Name: FTL, MGC71996, LFTD, NBIA3
User Note: Optimal dilutions for each application to be determined by the researcher
BACKGROUND: Mammalian ferritins consist of 24 subunits made up of 2 types of polypeptide chains, ferritin heavy chain and ferritin light chain. Ferritin heavy chains catalyze the first step in iron storage, the oxidation of Fe (II) , whereas ferritin light chains promote the nucleation of ferrihydrite, enabling storage of Fe (III) . Light chain ferritin is involved in cataracts by at least two mechanisms, hereditary hyperferritinemia cataract syndrome, in which light chain ferritin is overexpressed, and oxidative stress, an important factor in the development of ageing-related cataracts.